APOGEE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: APGE (Apogee Therapeutics, Inc.)
Last update: 5 hours ago83.03
1.22 (1.49%)
| Previous Close | 81.81 |
| Open | 82.76 |
| Volume | 686,018 |
| Avg. Volume (3M) | 897,343 |
| Market Cap | 6,255,471,616 |
| Price / Book | 6.96 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Apogee Therapeutics, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.70 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 2,048,647 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Wedbush, 14.42%) | Buy |
| Median | 88.50 (6.59%) | |
| Low | 82.00 (RBC Capital, -1.24%) | Hold |
| Average | 88.50 (6.59%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 68.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 82.00 (-1.24%) | Hold | 68.50 |
| Wedbush | 03 Mar 2026 | 95.00 (14.42%) | Buy | 68.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HENDERSON JANE | - | 80.75 | -2,000 | -161,500 |
| Aggregate Net Quantity | -2,000 | |||
| Aggregate Net Value ($) | -161,500 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 80.75 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENDERSON JANE | Officer | 01 May 2026 | Automatic sell (-) | 2,000 | 80.75 | 161,500 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |